AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01467141
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily
Trial: NCT00702858
Drug: Blue Citrus
RxNorm normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Midnight Blue Citrus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
Trial: NCT00702858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
Trial: NCT00317993
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00317993
Drug: ezetimibe plus simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03473340
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks
Trial: NCT01212991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Trial: NCT04035668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Trial: NCT02150291
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03325010
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active dosage form
Trial: NCT00902057
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline subcutaneous
Trial: NCT01489319
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Trial: NCT01489319
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Trial: NCT03073200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02461667
Drug: SRP plus Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Trial: NCT03812380
Drug: EffCaMgCit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Trial: NCT00981149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo match duloxetine for 6 week period.
Trial: NCT02760940
Drug: oral liposomal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
Trial: NCT01514019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule(Capsules filled up with lactose)
Trial: NCT01962441
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT00941655
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes.
Trial: NCT00609167
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m\^2 PO days 1, 8, 15 \& 22
Trial: NCT00088140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00404417
Drug: Botulinum Toxin A / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin A at first injection / Placebo at second injection
Trial: NCT00404417
Drug: Botulinum Toxin A / Botulinum Toxin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
Trial: NCT00404417
Drug: Placebo / Botulinum Toxin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at first injection / Botulinum Toxin A at second injection
Trial: NCT00404417
Drug: Placebo / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at first injection / Placebo at second injection
Trial: NCT00327106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
Trial: NCT01167088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02731885
Drug: ABX464 Single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Trial: NCT01504256
Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)
Trial: NCT01504256
Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)
Trial: NCT03268733
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet 5 mg
Trial: NCT02513186
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT00659893
Drug: PEP005 Topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05%, two day dose
Trial: NCT02102789
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
Trial: NCT04561219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a day for 5 days
Trial: NCT02102789
Drug: HAI
RxNorm normalized name: THAIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Trial: NCT02159066
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 and MEK162 (Part I)
Trial: NCT02159066
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 and MEK162 (Part I)
Trial: NCT02159066
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 + MEK162 + LEE011 (Part II)
Trial: NCT02159066
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 + MEK162 + BGJ398 (Part II)
Trial: NCT02159066
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 + MEK162 + BKM120 (Part II)
Trial: NCT02159066
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LGX818 + MEK162 + INC280 (Part II)
Trial: NCT00153036
Drug: rt-PA 0.9 mg/kg verum or placebo Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00423657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
Trial: NCT01040728
Drug: Placebo (for Olodaterol (BI1744)l)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olodaterol low and high dose) delivered by Respimat
Trial: NCT01040728
Drug: Placebo (for Tiotropium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Trial: NCT02748863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
Trial: NCT02138006
Drug: Standard insulin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Mixtard
Trial: NCT01231568
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
Trial: NCT01231568
Drug: Regimen D
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
Trial: NCT02574520
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml once at end of surgery
Trial: NCT01353404
Drug: Sequence 1
RxNorm normalized name: Antihemophilic Factor (Recombinant) Porcine Sequence 1 U Intravenous Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
Trial: NCT01353404
Drug: Sequence 5
RxNorm normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
Trial: NCT03091010
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
Trial: NCT03204396
Drug: 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
Trial: NCT02557542
Drug: Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous ablation
Trial: NCT02314117
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT02314117
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT00523107
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week
Trial: NCT00523107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml normal saline t.i.w. per week
Trial: NCT04189705
Drug: Mucosta Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 100mg
Trial: NCT01611311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Trial: NCT00740194
Drug: Aromatase inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole
Trial: NCT00740194
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermestril
Trial: NCT01320358
Drug: ECMPS-IEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECMPS-IEM
Trial: NCT01660997
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00901394
Drug: B12-Folic Acid, nitrous oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline.
Trial: NCT03905525
Drug: CFZ533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological
Trial: NCT00702702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules daily for 3 months
Trial: NCT00274248
Drug: MLN518
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02525471
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase.
Trial: NCT00984477
Drug: AZD5122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of oral suspension
Trial: NCT00984477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of oral suspension
Trial: NCT00984477
Drug: AZD5122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion
Trial: NCT00475670
Drug: Taxane (docetaxel or paclitaxel)
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
Trial: NCT03717688
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment
Trial: NCT01961505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
Trial: NCT04325893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Trial: NCT01665092
Drug: Levo-Carnitine
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01665092
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02994719
Drug: Anti-Parkinson medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
Trial: NCT02052908
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03044743
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To modify immune micro-environment
Trial: NCT00523757
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00523757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02241148
Drug: Acetaminophen 500mg
RxNorm normalized name: ACETAMINOPHEN 500MG CAP
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg, tablets every 8 hours
Trial: NCT01814527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules that are identical to the treatment.
Trial: NCT00004925
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420576
Drug: DBT-Danggui Buxue Tang
RxNorm normalized name: Buxus sempervirens leafy twig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
Trial: NCT03142529
Drug: colon lotion
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
Trial: NCT02604446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02604446
Drug: usual pain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
Trial: NCT00275106
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00980330
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
Trial: NCT00980330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
Trial: NCT00275106
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00275106
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00275106
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00275106
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00275106
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00114816
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01679951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
Trial: NCT02920892
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg - 100 mg oral suspension (liquid)
Trial: NCT02920892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension (liquid)
Trial: NCT00003992
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003992
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01679951
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
Trial: NCT03827655
Drug: TAK-954 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-954 placebo-matching intravenous infusion.
Trial: NCT00290680
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no